Trial reportClinical neuropharmacology
A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.
Trial report in Clinical neuropharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Can ketamine and other glutamate receptor modulators be considered entactogens?Psychiatry research · 2025Pooled it
- The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.The Cochrane database of systematic reviews · 2021Pooled it
- D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.The international journal of neuropsychopharmacology · 2016Pooled it
- d-Cycloserine enhances durability of social skills training in autism spectrum disorder.Molecular autism · 2017Trial
- A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.Clinical neuropharmacologyTrial
- Social memory engram formation impairment in neuroligin-3 R451C knock-in mice is caused by disrupted prefrontal NMDA receptor-dependent potentiation.Communications biology · 2025Article
- Local activity alterations in individuals with autism correlate with neurotransmitter properties and ketamine-induced brain changes.Nature communications · 2025Article
- Autism Spectrum Disorder, Oral Implications, and Oral Microbiota.Children (Basel, Switzerland) · 2025Review
- Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Autism spectrum disorder and the role of nuclear hormone receptors: insights and therapeutic implications.Frontiers in neuroscience · 2025Review
- Excitatory/inhibitory imbalance in autism: the role of glutamate and GABA gene-sets in symptoms and cortical brain structure.Translational psychiatry · 2023Article
- SHANK3 in vagal sensory neurons regulates body temperature, systemic inflammation, and sepsis.Frontiers in immunology · 2023Article
- Possible role of NO/NMDA pathway in the autistic-like behaviors induced by maternal separation stress in mice.PloS one · 2023Article
- The Role of Zinc and NMDA Receptors in Autism Spectrum Disorders.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic.Molecules (Basel, Switzerland) · 2022Review
- Dysfunction of NMDA receptors in neuronal models of an autism spectrum disorder patient with a DSCAM mutation and in Dscam-knockout mice.Molecular psychiatry · 2021Article
- Research Progress in Vitamin A and Autism Spectrum Disorder.Behavioural neurology · 2021Review
- Glutamatergic Dysfunction and Synaptic Ultrastructural Alterations in Schizophrenia and Autism Spectrum Disorder: Evidence from Human and Rodent Studies.International journal of molecular sciences · 2020Review
- Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.Molecular neurobiology · 2020Article
- The Neurochemistry of Autism.Brain sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesAutism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pathophysiology of ASDs. D-Cycloserine (DCS), a partial glycineB agonist at the N-methyl-D-aspartic acid receptor site, has been shown to improve sociability in mouse models and a small human study. The sensitivity of the obligatory glycineB co-agonist binding site may change with daily administration of DCS as a result of agonist-induced desensitization. The efficacy of a "pulsed" once-weekly administration versus "daily" administration of DCS was compared.
methodsMales and females, ages 14 to 25 years, with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of an ASD were enrolled in a double-blind, randomized 10-week trial consisting of 8 weeks of active drug with either weekly or daily administration of 50 mg of DCS followed by a 2-week follow-up visit.
resultsFor the purposes of this study, no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3, which measures stereotypies/repetitive movements. When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003).
conclusionsD-Cycloserine was shown to be effective in improving stereotypic symptoms in older adolescents and young adults with ASDs measured by the Aberrant Behavior Checklist subscale 3. In addition, DCS was safe and well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.